For the latest on Thailand Medical Industry, Thailand Doctors, Thailand Medical Research, Thailand Hospitals, Thailand Wellness Initiatives and the latest Medical News

BREAKING NEWS
Nikhil Prasad  Fact checked by:Thailand Medical News Team Apr 15, 2026  1 hour, 24 minutes ago

Scientists Warn That Selective Androgen Receptor Modulators May Not Be Safer Than Anabolic Steroids

8211 Shares
facebook sharing button Share
twitter sharing button Tweet
linkedin sharing button Share
Scientists Warn That Selective Androgen Receptor Modulators May Not Be Safer Than Anabolic Steroids
Nikhil Prasad  Fact checked by:Thailand Medical News Team Apr 15, 2026  1 hour, 24 minutes ago
Medical News: A growing body of scientific evidence is raising serious concerns about the safety of Selective Androgen Receptor Modulators (SARMs), a class of compounds widely promoted as a safer alternative to traditional anabolic steroids. New research now suggests that this assumption may be misleading, with emerging data showing that SARMs carry risks that are more similar to steroids than previously believed.


New research reveals that SARMs may carry health risks comparable to traditional anabolic steroids
 

Understanding How These Compounds Affect the Body
Both SARMs and anabolic androgenic steroids influence the body by activating androgen receptors - key regulators responsible for muscle growth, bone density, red blood cell production, and male reproductive function. Traditional anabolic steroids, which are synthetic derivatives of testosterone, activate these receptors throughout multiple tissues in the body. This broad activation leads to significant muscle-building effects but also causes widespread side effects.
 
SARMs were developed to address this issue by selectively targeting androgen receptors in muscle and bone while minimizing activity in other organs such as the prostate and skin. Early laboratory studies suggested that this tissue-selective approach could reduce harmful effects. However, real-world evidence increasingly shows that this selectivity is incomplete.
 
Key Findings from the Latest Research
The study was conducted by researchers from the Department of Physiology, Medical Faculty, Medical University of Plovdiv, Bulgaria, who performed a comprehensive analysis of molecular, pharmacological, and clinical data comparing SARMs and anabolic steroids.
 
The findings reveal that while SARMs can increase lean muscle mass, the improvements in physical strength and functional performance are often inconsistent. This disconnect suggests that visible muscle gains may not necessarily translate into meaningful health or performance benefits.
 
Importantly, SARMs were also found to suppress natural testosterone production. This occurs because the body responds to external stimulation of androgen receptors by reducing its own hormone production. Although some studies suggest this suppression may be reversible, there is limited data on the long-term consequences of repeated or prolonged use.
 
This Medical News report emphasizes a critical issue - many users are drawn to SARMs under the assumption that they are a safer alternative, yet emerging evidence indicates that these compounds still significantly interfere with the body’s hormonal balance.
 
Emerging Safety Risks Mirror Steroid Effects
Anabolic steroids have long been associated with serious health risks, including cardiovascular disease, liver toxicity, infertility, and psychological disturbances such as mood swings and aggression. These risks are well established through decades of clinical and epidemiological research.
&am p;nbsp;
SARMs, although designed to reduce such risks, are now showing concerning safety signals. Reports have documented liver injury, unfavorable changes in cholesterol levels, and potential cardiovascular effects. Some evidence also points to an increased risk of tendon injuries, similar to those seen with steroid use.
 
Additionally, SARMs have demonstrated dose-dependent suppression of the hypothalamic–pituitary–gonadal axis, confirming that even selective activation of androgen receptors can disrupt the body’s endocrine system.
 
Lack of Long-Term Data Raises Uncertainty
One of the most significant concerns surrounding SARMs is the absence of long-term safety data. Most clinical studies have been short in duration and involve small sample sizes, making it difficult to assess the full spectrum of potential risks.
This lack of data is particularly troubling given the increasing popularity of SARMs in bodybuilding and fitness communities, where they are often used without medical supervision.
 
Unregulated Market Increases Public Health Risks
Compounding the issue is the largely unregulated market for SARMs. These compounds are frequently sold online as “research chemicals” or mislabeled supplements. Studies have shown that many products contain incorrect dosages or are contaminated with other substances, including anabolic steroids.
 
This inconsistency not only undermines safety claims but also exposes users to additional unknown risks.
 
Conclusion
In conclusion, while Selective Androgen Receptor Modulators were developed to provide the muscle-building benefits of anabolic steroids with fewer side effects, current evidence suggests that this goal has not yet been fully achieved. SARMs still disrupt natural hormone production, carry potential risks to the liver and cardiovascular system, and lack sufficient long-term safety data. Their perceived safety advantage appears to be relative rather than absolute. Until more robust and long-term clinical studies are conducted, both SARMs and anabolic steroids should be approached with caution, particularly outside regulated medical settings, as their risks may outweigh their intended benefits.
 
The study findings were published in the peer reviewed journal: Future Pharmacology.
https://www.mdpi.com/2673-9879/6/2/25
 
For the latest on SARMs and anabolic steroids, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/articles/health-news
 

MOST READ

Apr 06, 2026  9 days ago
Nikhil Prasad
Mar 08, 2026  1 month ago
Nikhil Prasad
Mar 06, 2026  1 month ago
Nikhil Prasad